Le Lézard
Classified in: Health
Subject: PDT

InventHelp Inventor Develops Automatic Narcan Administering Device (OSK-518)


PITTSBURGH, May 22, 2024 /PRNewswire/ -- "I wanted to create a device for opioid users that would provide life-saving doses of Narcan and call 911 emergency assistance if needed," said an inventor, from Los Angeles, Calif., "so I invented THE LONELY STONER. My design could help prevent an overdose situation from leading to a potentially fatal outcome."

The patent-pending invention provides an arm or wrist wearable smart health monitoring, automatic Narcan administering device. It also would summon emergency assistance for persons having opioid dependency issues. As a result, it enhances safety and it helps save lives. The invention features an innovative design that is easy to use so it is ideal for individuals with opioid dependency issues. Additionally, a prototype model is available upon request.

The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 22-OSK-518, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp


These press releases may also interest you

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
India-Based Dhiti Omics is Now Live on SOPHiA DDMtm
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI: Appointment of Adviser
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
If You Purchased, Paid, or Provided Reimbursement for Some or All of the Price of Branded Lipitor® or its Generic Equivalent, Atorvastatin Calcium, You Could Get Money From a Settlement
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

More news about Health...


News published on and distributed by: